Narcostop 5 mg/ml, solution for injection for cats and dogs

Main information

  • Trade name:
  • Narcostop 5 mg/ml, solution for injection for cats and dogs
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Narcostop 5 mg/ml, solution for injection for cats and dogs
    Netherlands
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • atipamezole
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • NL/V/0139/001
  • Authorization date:
  • 30-03-2011
  • EU code:
  • NL/V/0139/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

PartIB Summaryofproductcharacteristics,labelandpackageinsert

SummaryofProductCharacteristics

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Narcostop5mg/ml–SolutionforInjectionforCatsandDogs

(NL,AT,BE,CZ,EL,FR,HU,IS,IE,LU,PL,SK)

Sedastop5mg/ml–SolutionforInjectionforCatsandDogs

(SE,NO,DK,ES,PT,IT,UK,FI)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1mlsolutionforinjectioncontains:

Activesubstance:

Atipamezole(ashydrochloride)4.27mg

Equivalentto5.0mgofatipamezolehydrochloride

Excipients:

Methylparahydroxybenzoate(E218)1.0mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Aclearcolourless,sterileaqueoussolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogsandcats

4.2 Indicationsforuse,specifyingthetargetspecies

Atipamezolehydrochlorideisindicatedforreversalofthesedativeeffectsand

cardiovascular effects oncirculation afteruseofalpha-2-agonistslikemedetomidine

anddexmedetomidineindogsandcats.

4.3 Contraindications

Theproductshouldnotbeusedin:

-Breedinganimals

-Animalssufferingfromliver-orrenaldiseases

Seealsosection4.7

4.4 Specialwarningsforeachtargetspecies

Makesuretheanimalhasregained anormalswallowingreflexbeforeanyfoodor

drinkisoffered.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Afteradministrationoftheproduct,theanimalsshouldbeallowedtorestinaquiet

place.Duringrecoverytimeanimalsshouldnotbeleftunattended.

Duetodifferentdosingrecommendationscautionshouldbetakenifusingtheproduct

off-labelinanimalsotherthanthetargetspecies.

Ifothersedativesthanmedetomidinearegiven itmustbekeptinmindthattheeffects

ofthoseotheragentsmaypersistafterreversalof(dex)medetomidine.

Atipamezoledoesnotreversetheeffectofketamine,whichmaycauseseizuresin

dogsandelicitcrampsincatswhenusedalone.Donotuseatipamezoleearlierthan

30-40minutesafterconcomitantadministrationofketamine.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Duetothepotentpharmacologicalactivityofatipamezole,skin-,eye-andmucous

membrane-contactwiththisproductshouldbeavoided.Incaseofaccidentalspillage

washtheaffectedareaimmediatelywithcleanrunning water.Seekmedicalattentionif

irritationpersists.Removecontaminatedclothesthatareindirectcontactwiththe

skin.

Careshouldbetakentoavoidaccidentalingestionorself-injection.Ifaccidental

ingestion orself-injectionoccurs,seekmedicalattentionimmediately,showingacopy

ofthepackageleaflet.

4.6 Adversereactions(frequencyandseriousness)

Atransienthypotensiveeffecthasbeenobservedduringthefirst10minutespost-

injectionofatipamezolehydrochloride.Inrarecaseshyperactivity,tachycardia,

salivation,atypicalvocalization,muscletremor,vomiting,increasedrespiratoryrate,

uncontrolledurinationanduncontrolleddefecationmayoccur.

Invery rarecasesrecurrenceofsedationmayoccurortherecoverytimemaynotbe

shortenedafteradministrationofatipamezole.

Incats,whenusinglowdosestopartiallyreversetheeffectsofmedetomidineor

dexmedetomidine,thepossibility ofhypothermia(evenwhenarousedfromsedation)

shouldbeguardedagainst.

4.7 Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduring

pregnancyandlactation.

Theproductshouldnotbeadministeredtopregnantandlactatingbitchesandqueens

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Asimultaneousadministrationofatipamezolewithothercentrallyactingmedicinal

productsasdiazepam,acepromazineoropiatesisnotrecommended.

4.9 Amounttobeadministeredandadministrationroute

Forsingleintramuscularinjection.

Atipamezolehydrochlorideisadministered15-60minaftermedetomidineor

dexmedetomidinehydrochlorideadministration.

Dogs:theintramuscularatipamezolehydrochloridedose[inµg]isfivetimesthatof

thepreviousmedetomidinehydrochloridedoseortentimesthatofthe

dexmedetomidinehydrochloridedose.Duetothe5-foldhigherconcentrationofthe

activeingredient(atipamezolehydrochloride)inthisproductcomparedtothatof

preparationscontaining1mgmedetomidinehydrochloridepermlandthe10-fold

higherconcentrationcomparedtothatofpreparationscontaining0.5mg

dexmedetomidinehydrochloride,anequalvolumeofeachpreparationisrequired.

DosageexampleDogs:

Medetomidine1mg/mlsolution

forinjectiondosage Narcostop5mg/mlsolutionfor

injectionfordogsdosage

0.04ml/kgbodyweight(bw),

i.e.40µg/kgbw 0.04ml/kgbw,

i.e.200µg/kgbw

Dexmedetomidine0.5mg/ml

solutionforinjectiondosage Narcostop5mg/mlsolutionfor

injectionfordogsdosage

0.04ml/kgbodyweight(bw),

i.e.20µg/kgbw 0,04ml/kgbw,

i.e.200µg/kgbw

Cats:theintramuscularatipamezolehydrochloridedose[in µg]istwo-and-a-halftimes

thatofthepreviousmedetomidinehydrochloridedoseorfivetimesthatofthe

dexmedetomidinehydrochloridedose.Duetothe5-foldhigherconcentrationofthe

activeingredient(atipamezolehydrochloride)inthisproductcomparedtothatof

preparationscontaining1mgmedetomidinehydrochloridepermlandthe10-fold

higherconcentrationcomparedtothatofpreparationscontaining0.5mg

dexmedetomidinehydrochloride,halfthevolumeoftheproducttothatofthe

previouslyadministeredmedetomidineordexmedetomidineshouldbegiven.

DosageexampleCats:

Medetomidine1mg/mlsolution

forinjectiondosage Narcostop5mg/mlsolutionfor

injectionforcatsdosage

0.08ml/kgbodyweight(bw),

i.e.80µg/kgbw 0.04ml/kgbw,

i.e.200µg/kgbw

Dexmedetomidine0.5mg/ml

solutionforinjectiondosage Narcostop5mg/mlsolutionfor

injectionforcatsdosage

0.08ml/kgbodyweight(bw),

i.e.40µg/kgbw 0,04ml/kgbw,

i.e.200µg/kgbw

Therecoverytimeisshortenedtoapproximately5minutes.Theanimalbecomes

mobileafterapproximately10minutesafteradministrationoftheproduct.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdoseofatipamezolehydrochloridemayresultintransienttachycardiaandover-

alertness(hyperactivity,muscletremor).Ifnecessary,thesesymptomsmaybe

reversedbya(dex)medetomidinehydrochloridedosewhichislowerthantheusually

usedclinicaldose.

Ifatipamezolehydrochlorideisinadvertently administeredtoananimalnotpreviously

treatedwith(dex)medetomidinehydrochloride,hyperactivityandmuscletremormay

occur.Theseeffectsmaypersistforabout15minutes.Over-alertnessinthecatisbest

handledbyminimizingexternalstimuli.

4.11Withdrawalperiods

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

ATCvetcode: QV03AB90

Pharmacotherapeuticgroup: 

2-receptorantagonist(Antidote)

5.1 Pharmacodynamicproperties

Atipamezoleisapotentandselectiveα2-receptorblockingagent(α2-antagonist),

whichpromotesthereleaseoftheneurotransmitternoradrenalinein thecentralaswell

asintheperipheralnervoussystems.Thisleadstoactivationofthecentralnervous

systemduetosympatheticactivation.Otherpharmacodynamiceffectsasforexample

influenceofthecardiovascularsystemareonlymild–butatransientdecreaseof

bloodpressuremaybeseenwiththefirst10minutesafterinjectionofatipamezole

hydrochloride.

Asaα2-antagonist,atipamezoleiscapableofeliminating(orinhibiting)theeffectsof

theα2-receptoragonist,medetomidineordexmedetomidine.Thusatipamezole

reversesthesedativeeffectsof(dex)medetomidinehydrochlorideindogsandcatsto

normalandmayleadtoatransientincreaseinheartrate.

5.2 Pharmacokineticparticulars

Atipamezolehydrochlorideisrapidlyabsorbedafterintramuscularinjection.The

maximalconcentrationinthecentralnervoussystemisreachedin10-15minutes.

Volumeofdistribution(V

)isabout1–2.5l/kg.Thehalf-lifeofatipamezole

hydrochlorideisreportedtobeapproximately1hour.Atipamezolehydrochloride

israpidlyandcompletelymetabolized.Themetabolitesaremainlyexcretedinurine

andinasmallamountinfaeces.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Methylparahydroxybenzoate(E218)

Sodiumchloride

Hydrochloricacid(forpH-adjustment)

Sodiumhydroxide(forpH-adjustment)

Waterforinjections

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelflifeafterfirstopeningtheimmediatepackaging:28days.

6.4 Specialprecautionsforstorage

Keepthevialintheoutercartoninordertoprotectfromlight.

Donotfreeze.

6.5 Natureandcompositionofimmediatepackaging

Clearglass(typeI)vialwithbromobutylrubberstopper(typeI)containing10ml

solutionforinjection.

Cardboardboxwith1vialcontaining10ml.

Cardboardboxwith5vialscontaining10ml.

Cardboardboxwith10vialscontaining10ml.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Willeskop212

NL-3421GWOudewater.

TheNetherlands

8. MARKETINGAUTHORISATIONNUMBER

9. DATEOFFIRSTAUTHORISATION

PARTICULARSTOAPPEARONTHEOUTERPACKAGE

Carton

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

NarcostopSedastop5mg/ml-SolutionforInjectionforCatsandDogs

Atipamezolehydrochloride

2. STATEMENTOFACTIVEANDOTHERSUBSTANCES

1mlsolutionforinjectioncontains:

Activesubstance:

Atipamezole(ashydrochloride) 4.27mg

Equivalentto5.0mgofatipamezolehydrochloride

Excipients:

Methylparahydroxybenzoate(E218) 1.0mg

3. PHARMACEUTICALFORM

Solutionforinjection

4. PACKAGESIZE

10ml,5x10ml,10x10ml

5. TARGETSPECIES

Fordogsandcats.

6. INDICATIONS

Atipamezolehydrochlorideisindicated forreversalofthesedativeeffectsand cardiovascular

effects oncirculation afteruseofalpha-2-agonistslikemedetomidineand

dexmedetomidineindogsandcats.7.METHOD AND ROUTE(S) OF

ADMINISTRATION

Forsingleintramuscularuse.Readthepackageleafletbeforeuse.

8. WITHDRAWALPERIOD

Notapplicable

9. SPECIALWARNING(S),IFNECESSARY

Accidentalinjectionisdangerous.Readpackageleafletbeforeuse.

10.EXPIRYDATE

EXP:

Shelflifeafterfirstopeningthecontainer:28days.

Oncebroached,useby………….

Batch:

Thisveterinarymedicinalproductmustnotbemixed withotherveterinarymedicinalproducts

11.SPECIALSTORAGECONDITIONS

Keepthevialintheoutercartoninordertoprotectfromlight.

12.SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTSOR

WASTEMATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

13.THEWORDS“FORANIMALTREATMENTONLY”ANDCONDITIONSOR

RESTRICTIONSREGARDINGSUPPLYANDUSE,ifapplicable

Foranimaltreatmentonly.

Tobesuppliedonlyonveterinaryprescription.

14.THEWORDS“KEEPOUTOFTHEREACHANDSIGHTOFCHILDREN”

Keepoutofthereachandsightofchildren.

15.NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

LeVetB.V.

Willeskop212

3421GWOudewater

TheNetherlands

16.MARKETINGAUTHORISATIONNUMBER(S)

Formatiert:Einzug:ErsteZeile:0cm

Lot:

MINIMUMPARTICULARSTOAPPEARONSMALLIMMEDIATEPACKAGING

UNITS

Vial

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

NarcostopSedastop5mg/ml-SolutionforInjectionforCatsandDogs

Atipamezolehydrochloride

2. QUANTITYOFTHEACTIVESUBSTANCE

1mlsolutionforinjectioncontains:

Activesubstance:

Atipamezole(ashydrochloride 4.27mg

Equivalentto5.0mgofatipamezolehydrochloride

Excipients:

Methylparahydroxybenzoate(E218) 1.0mg

3. CONTENTSBYWEIGHT,BYVOLUMEORBYNUMBEROFDOSES

10ml

4. ROUTE(S)OFADMINISTRATION

Forsingleintramuscularuse.

5. WITHDRAWALPERIOD

Notapplicable.

6. BATCHNUMBER

Batch:

7. EXPIRYDATE

EXP:

Onceopened,useby28days.

Keepthevialintheoutercartoninordertoprotectfromlight.

8. THEWORDS“FORANIMALTREATMENTONLY”

Foranimaltreatmentonly.

Tobesuppliedonlyonveterinaryprescription.

PACKAGELEAFLET

NarcostopSedastop5mg/ml-SolutionforInjectionforCatsandDogs

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDER

AND OF THE MANUFACTURING AUTHORISATION HOLDER

RESPONSIBLEFORBATCHRELEASE,IFDIFFERENT

Marketingauthorisationholder:

LeVetB.V.

Willeskop212

3421GWOudewater

TheNetherlands

Manufacturerforthebatchrelease:

ProdulabPharmaB.V.

Forellenweg16

4941SJRaamsdonksveer

TheNetherlands

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

NarcostopSedastop5mg/ml-SolutionforInjectionforCatsandDogs

Activesubstance:Atipamezolehydrochloride

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER

INGREDIENT(S)

Narcostopisanaqueoussolutionforinjectioncontaining:

Activesubstance:

Atipamezole(ashydrochloride 4.27mg/ml

Equivalentto5.0mgofatipamezolehydrochloride

Excipients:

Methylparahydroxybenzoate(E218) 1.0mg/ml

4. INDICATION(S)

DogsandCats:

Atipamezolehydrochlorideisindicated forreversalofthesedativeeffectsand cardiovascular

effects oncirculation afteruseofalpha-2-agonistslikemedetomidineanddexmedetomidine

indogsandcats.

5. CONTRAINDICATIONS

Theproductshouldnotbeusedin:

-Breedinganimals

-Animalssufferingfromliver-orrenaldiseases

6. ADVERSEREACTIONS

Atransienthypotensiveeffecthasbeenobservedduring thefirst10minutespost-injectionof

atipamezolehydrochloride.Inrarecaseshyperactivity,tachycardia,salivation,atypical

vocalization,muscletremor,vomiting,increasedrespiratoryrate,uncontrolledurinationand

uncontrolleddefecationmayoccur.

Invery rarecasesrecurrenceofsedationmayoccurortherecoverytimemaynotbeshortened

afteradministrationofatipamezole.

Incats,whenusinglowdosestopartiallyreversetheeffectsofmedetomidineor

dexmedetomidine,thepossibility ofhypothermia(evenwhenarousedfromsedation)should

beguardedagainst.

Ifyounoticeanyseriouseffectsoranyothereffectsnotmentionedinthisleaflet,please

informyourveterinarysurgeon.”

7. TARGETSPECIES

DogsandCats

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF

ADMINISTRATION

Forsingleintramuscularinjection.

Atipamezolehydrochlorideisadministered15-60minaftermedetomidineor

dexmedetomidinehydrochlorideadministration.

Dogs:theintramuscularatipamezolehydrochloridedose[inµg]isfivetimesthatofthe

previousmedetomidinehydrochloridedoseortentimesthatofthedexmedetomidine

hydrochloridedose.Duetothe5-foldhigherconcentrationoftheactive ingredient

(atipamezolehydrochloride)inthisproductcomparedtothatofpreparationscontaining1

mgmedetomidinehydrochloridepermland the10-foldhigherconcentrationcomparedtothat

ofpreparationscontaining0.5mgdexmedetomidinehydrochloride,anequalvolumeofeach

preparationisrequired.

DosageexampleDogs:

Medetomidine1mg/mlsolution

forinjectiondosage Narcostop5mg/mlsolutionfor

injectionfordogsdosage

0.04ml/kgbodyweight(bw),

i.e.40µg/kgbw 0.04ml/kgbw,

i.e.200µg/kgbw

Dexmedetomidine0.5mg/ml

solutionforinjectiondosage Narcostop5mg/mlsolutionfor

injectionfordogsdosage

0.04ml/kgbodyweight(bw), 0,04ml/kgbw,

i.e.20µg/kgbw i.e.200µg/kgbw

Cats:theintramuscularatipamezolehydrochloridedose[in µg]istwo-and-a-halftimesthat

ofthepreviousmedetomidinehydrochloridedoseorfivetimesthatofthedexmedetomidine

hydrochloridedose.Duetothe5-foldhigherconcentrationoftheactive ingredient

(atipamezolehydrochloride)inthisproductcomparedtothatofpreparationscontaining1

mgmedetomidinehydrochloridepermland the10-foldhigherconcentrationcomparedtothat

ofpreparationscontaining0.5mgdexmedetomidinehydrochloride,halfthevolumeofthe

producttothatofthepreviouslyadministeredmedetomidineordexmedetomidineshouldbe

given.

DosageexampleCats:

Medetomidine1mg/mlsolution

forinjectiondosage Narcostop5mg/mlsolutionfor

injectionforcatsdosage

0.08ml/kgbodyweight(bw),

i.e.80µg/kgbw 0.04ml/kgbw,

i.e.200µg/kgbw

Dexmedetomidine0.5mg/ml

solutionforinjectiondosage Narcostop5mg/mlsolutionfor

injectionforcatsdosage

0.08ml/kgbodyweight(bw),

i.e.40µg/kgbw 0,04ml/kgbw,

i.e.200µg/kgbw

Therecoverytimeisshortenedtoapproximately5 minutes.Theanimalbecomesmobileafter

approximately10minutesafteradministrationoftheproduct.

9. ADVICEONCORRECTADMINISTRATION

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixed

withotherveterinarymedicinalproducts.

10. WITHDRAWALPERIOD

Notapplicable

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Keepthevialintheoutercartoninordertoprotectfromlight.Donotfreeze

Donotuseaftertheexpirydatestatedonthelabelandonthecarton.

Shelf-lifeafterfirstopeningtheimmediatepackaging: 28days.

12. SPECIALWARNING(S)

Specialprecautionsforuseinanimals

Afteradministrationoftheproduct,theanimalsshouldbeallowedtorestinaquietplace.

Duringrecoverytimeanimalsshouldnotbeleftunattended.

Makesuretheanimalhasregained anormalswallowingreflexbeforeanyfoodordrinkis

offered.

Duetodifferentdosingrecommendationscautionshouldbetakenifusingtheproductoff-

labelinanimalsotherthanthetargetspecies.

Ifothersedativesthanmedetomidinearegivenitmustbekeptinmindthattheeffectsof

thoseotheragentsmaypersistafterreversalof(dex)medetomidine.

Atipamezoledoesnotreversetheeffectofketamine,whichmaycauseseizuresindogsand

elicitcrampsincatswhenusedalone.Donotuseatipamezoleearlierthan30-40 minutesafter

concomitantadministrationofketamine.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Duetothepotentpharmacologicalactivityofatipamezole,skin-,eye-andmucous

membrane-contactwiththisproductshouldbeavoided.Incaseofaccidentalspillagewash

theaffectedareaimmediatelywithcleanrunningwater.Seekmedicalattentionifirritation

persists.Removecontaminatedclothesthatareindirectcontactwiththeskin.

Careshould betaken toavoidaccidentalingestionorself-injectionIfaccidentalingestionor

self-injectionoccurs,seekmedicalattentionimmediately,showingacopyofthepackage

leaflet.

Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeen establishedduringpregnancyand

lactation.

Theproductshouldnotbeadministeredtopregnantandlactatingbitchesandqueens

Interactionwithothermedicinalproductsandotherformsofinteraction

Asimultaneousadministrationofatipamezolewithothercentrallyactingmedicinalproducts

asdiazepam,acepromazineoropiatesisnotrecommended.

Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdoseofatipamezolehydrochloridemayresultin transienttachycardiaandover-alertness

(hyperactivity,muscletremor).Ifnecessary,thesesymptomsmaybereversedbya

(dex)medetomidinehydrochloridedosewhichislowerthantheusuallyusedclinicaldose.

Ifatipamezolehydrochlorideisinadvertently administeredtoan animalnotpreviouslytreated

with(dex)medetomidinehydrochloride,hyperactivityandmuscletremormayoccur.These

effectsmaypersistforabout15minutes.Over-alertnessinthecatisbesthandledby

minimizingexternalstimuli.

Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixed

withotherveterinarymedicinalproducts.

13.SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

<MM/YYYY>

15. OTHERINFORMATION

1x1glassvialwith10ml.

5x1glassvialswith10ml.

10x1glassvialwith10ml.

Notallpacksizesmaybemarketed.

Tobesuppliedonlyonveterinaryprescription.

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

29-5-2018

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Active substance: Ambroxol hydrochloride) - Orphan designation - Commission Decision (2018)3384 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/236/17

Europe -DG Health and Food Safety